PSMA Response in Metastasized Hormone Sensitive Prostate Cancer

NCT05161728 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-01-09

No results posted yet for this study

Summary

PSMA-PET/CT response measurements after LHRH agonist and upfront therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

PSMA-PET/CT

PSMA-PET/CT

Sponsors & Collaborators

  • Roderick van den Bergh

    lead OTHER

Principal Investigators

  • Marnix Lam, MD PhD · UMC Utrecht

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2025-10-19
Completion
2025-10-19

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05161728 on ClinicalTrials.gov